Dosecann

In May 2026, Dosecann’s mix concentrated in Capsules at 38.6% share with year-over-year decline of 61.7% and month-over-month decline of 7.5%, while Oil held 33.1% share with a 34.7% YoY drop and a 7.8% MoM dip. Vapor Pens rose to 24.1% share with a 41.0% MoM increase but carried a 34.7% YoY decline, and Topical, at 2.8% share, jumped 48.6% MoM against a 94.2% YoY fall. Concentrates remained small at 1.5% share but surged 170.9% MoM with no YoY baseline, and the brand’s average price fell 9.5% YoY to $27.63. The pattern implies a pivot away from legacy Capsules and Oil toward faster-recovering inhalables and niche formats, using price compression and mix shifts to counteract a 57.6% brand-level YoY contraction.

These shifts position Dosecann to lean on momentum pockets where rank gains are plausible, as indicated by a rank of 9 in Oil in Alberta despite a 7.8% MoM decline and a 34.7% YoY decline. Vapor Pens’ 41.0% MoM growth alongside a 24.1% share suggests headroom to trade consumers from Capsules, which fell 7.5% MoM and 61.7% YoY, into formats with lower YoY drag; conversely, Oil’s 33.1% share with declining trajectory signals a need to defend core while reallocating toward Concentrates’ 170.9% MoM spike and Topical’s 48.6% MoM rise. The implication is that Dosecann’s near-term positioning benefits from emphasizing inhalable and high-velocity niche SKUs to stabilize share while using Oil’s rank foothold to maintain visibility as Capsules continue to contract.